Dealmaking

Busy biopharma M&A activity closed out 2018

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]

Biopharma licensing finished with a strong Q4

During the fourth quarter of 2018, Cortellis Competitive Intelligence   registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]

Biopharma M&A engine fires up as new year rings in big deals

Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the […]

Licensing deals driving the life sciences industry in Q3: notes and trends

During the third quarter of 2018, Cortellis Competitive Intelligence registered 984 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $26 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,060 and $20.8 billion in the second quarter and 1,158 and $33.6 billion […]

Q3 M&A deals driving the life sciences industry

Trends in M&A volume and deal value During the third quarter of 2018, Cortellis Deals Intelligence registered 131 new mergers and acquisitions (M&A) with a total disclosed deal value of $16 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 113 and $104.6 billion in the second […]

Key Q2 partnerships driving biopharma

Introduction During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and $35.6 billion in the first quarter and 1,104 and $13.6 […]

Women have their say as all-female panel talks biopharma investment, technology trends

This article is part of an ongoing series from Clarivate Analytics celebrating women in STEM with profiles of female scientists, inventors, researchers, and corporate leaders featured in BioWorld, Derwent, Web of Science, and Publons. See more articles in this series, or follow our online campaign using #WomenAtClarivate. One of the hottest tickets in town during […]